EP Edge Journal Watch

Niraj Sharma MD FACC FHRS
  • 5.0 (10)
  • Life Sciences

Welcome to EP Edge Journal Watch — where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this bi-weekly podcast distills high-impact cardiovascular and EP research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal — not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve

  1. 1d ago

    EP Edge® Journal Watch Issue 31, August 2026: Caffeine, Wine, Atrial Fibrillation, Pulsed-Field Ablation and Sudden Cardiac Death

    In EP Edge® Journal Watch Issue 31, August 2026, Dr. Sharma examine new evidence that challenges several familiar assumptions in cardiac electrophysiology. Should patients with atrial fibrillation routinely stop drinking coffee? An American Heart Association scientific statement reviews the cardiovascular effects of caffeine, including randomized evidence showing a 39% lower risk of recurrent AF among habitual coffee drinkers who continued coffee after cardioversion. The discussion separates ordinary coffee consumption from energy drinks and concentrated caffeine while considering premature ventricular contractions, blood pressure, sleep, and individualized patient counseling. The episode also investigates whether wine adds cardiovascular benefit to the Mediterranean diet. The apparent benefit weakened when moderate drinkers were compared with very-light drinkers, demonstrating how the reference group can change the statistical narrative. Importantly, these studies did not evaluate AF outcomes and do not support prescribing wine as cardiovascular therapy. Other studies covered include: • Pulsed-field ablation for persistent AF, with pooled one-year freedom from atrial arrhythmia of 72.3%, but no proven superiority over thermal ablation. • Broad and predominantly left-sided pulmonary vein reconnection patterns during redo procedures after pentaspline pulsed-field ablation. • Real-world Sphere-9 safety reports involving ventricular arrhythmias, implanted-device interactions, stroke, AV block, and other signals, interpreted in the absence of a procedural denominator. • The SMARTBEATS randomized trial of smartphone rhythm monitoring before cardioversion, which prevented approximately one same-day cancellation for every six patients monitored. • Autopsy-based sudden cardiac death research showing that myocardial infarction accounted for 41% of confirmed sudden cardiac deaths and highlighting the limitations of ejection fraction alone. • End-tidal carbon dioxide trajectories during out-of-hospital cardiac arrest and why no single value should become a stand-alone termination rule. • Atrial fibrillation, bradycardia, conduction disease, and ventricular ectopy in masters athletes, reinforcing that exceptional fitness does not provide immunity from clinically important arrhythmias. Listen for the study rationale, methodology, clinically meaningful statistics, limitations, and the EP Edge take on how these findings may influence practice. Complete references, graphics, and detailed analysis are available through the LinkedIn newsletter EP Edge® Journal Watch and at epedge.substack.com.

    EP Edge® Journal Watch Issue 31, August 2026: Caffeine, Wine, Atrial Fibrillation, Pulsed-Field Ablation and Sudden Cardiac Death

  2. Jul 27

    EP Edge® Journal Watch Issue 30: VISION AF, Pulsed Field Ablation Safety, PACE-HF and Conduction System Pacing | July 2026

    In EP Edge® Journal Watch Issue 30, July 2026, we explore the next phase of cardiac electrophysiology, from pulsed field ablation durability and physiologic pacing to neuromodulation, sleep, fitness, and lifetime arrhythmia risk. We begin with the first-in-human VISION AF study, which evaluates an endoscope-enabled pulsed field ablation balloon that allows direct visualization of the electrode-tissue interface. Chronic invasive remapping provides a close look at pulmonary vein isolation durability and raises an important question: could seeing tissue contact become the next major advance in PFA workflow?  Two additional studies examine practical PFA safety signals. One evaluates hemolysis-associated acute kidney injury, pulse count, chronic kidney disease, extensive left atrial ablation, and whether protocol-based hydration can reduce renal risk. Another quantifies acute blood pressure drops during circular-array PFA and identifies the first pulmonary vein treatment as the period of greatest hemodynamic vulnerability.  The pacing and ventricular arrhythmia section includes:  The randomized PACE-HF trial, comparing left bundle branch area pacing with conventional right ventricular pacing  A preclinical comparison of left bundle branch area antitachycardia pacing and right ventricular ATP  Pulsed ultrahigh-frequency spinal cord stimulation as a potential neuromodulation strategy after myocardial infarction We then move beyond the EP laboratory to examine:  Insomnia and incident atrial fibrillation  The lifetime cardiovascular tradeoff between high cardiorespiratory fitness and AF risk  Whether the balance of moderate and vigorous physical activity influences cardiovascular and overall mortality Each paper is examined through its rationale, methodology, statistical meaning, limitations, and potential clinical consequences. Can direct tissue visualization improve PFA durability? Should PFA pulse count be treated as a biologic dose? Is right ventricular pacing still acceptable when substantial pacing is anticipated? Could the site of antitachycardia pacing determine whether VT terminates? How should clinicians incorporate sleep and exercise into arrhythmia prevention? This episode is intended for electrophysiologists, cardiologists, device specialists, fellows, researchers, and anyone following advances in pulsed field ablation, conduction system pacing, ventricular arrhythmia therapy, and preventive cardiology. Read the companion newsletter and subscribe to EP Edge® Journal Watch at epedge.substack.com.

    EP Edge® Journal Watch Issue 30: VISION AF, Pulsed Field Ablation Safety, PACE-HF and Conduction System Pacing | July 2026

  3. Jul 20

    EP Edge® Journal Watch Issue 29: Atrial Fibrillation Ablation vs Antiarrhythmic Drugs, CABANA Progression and Anticoagulation | July 2026

    In EP Edge® Journal Watch Issue 29, July 2026, we examine the evidence reshaping contemporary atrial fibrillation management and the rapidly changing role of catheter ablation. Two major meta-analyses compare catheter ablation with antiarrhythmic drug therapy, addressing rhythm efficacy, serious adverse events, hospitalization, treatment intolerance, and whether medications still deserve an automatic safety advantage. We also review real-world outcomes in older adults after prior antiarrhythmic drug exposure and ask whether another medication or catheter ablation is the more appropriate next step.  The episode then explores whether ablation can modify the natural history of AF. A CABANA analysis evaluates progression from paroxysmal to persistent AF, while new registry data challenge the assumption that asymptomatic AF represents a low-risk phenotype. The SUPPRESS-AF analysis examines whether low-voltage area ablation should be guided by the amount of abnormal atrial substrate rather than applied uniformly.  We also discuss:  Urgent versus elective inpatient AF ablation  Oral anticoagulation after apparently successful AF ablation  The age-dependent relationship between heart failure and ischemic stroke  The SLASH score for predicting AF recurrence after electrical cardioversion Each study is reviewed through its clinical rationale, methodology, statistical interpretation, limitations, and practical implications for electrophysiology practice. Should catheter ablation move earlier in the AF treatment pathway? Should symptom status continue to determine access to rhythm control? When is urgent inpatient ablation justified? Does successful ablation ever eliminate the need for anticoagulation? This episode is designed for cardiac electrophysiologists, cardiologists, fellows, researchers, and clinicians seeking a detailed, clinically relevant review of the latest atrial fibrillation evidence. Read the companion newsletter and subscribe to EP Edge® Journal Watch at epedge.substack.com.

    EP Edge® Journal Watch Issue 29: Atrial Fibrillation Ablation vs Antiarrhythmic Drugs, CABANA Progression and Anticoagulation | July 2026

  4. Jul 13

    EP Edge × HRS Podcast: CT-Guided VT Ablation & LAA Closure Without AF: InEurHeart and OPINION, Caveolae, Alcohol and AFib, Pulse check and Afib Diagnosis

    In this July 2026 episode of EP Edge Journal Watch, produced in collaboration with the Heart Rhythm Society (HRS), Mike Lloyd and Dr. Niraj Sharma review five studies with direct implications for contemporary cardiac electrophysiology practice. The anchor trials are InEurHeart, a randomized comparison of computed tomography-guided versus conventional catheter ablation for post–myocardial infarction ventricular tachycardia, and OPINION, which evaluates prophylactic surgical left atrial appendage occlusion during valvular heart surgery in patients without known pre-existing atrial fibrillation. Using the workflow gains seen with pulsed field ablation in AF as context, the discussion asks whether preprocedural cardiac CT can make ischemic VT ablation more efficient while preserving the essential role of functional mapping and why future AF risk should not automatically lead to surgical LAA closure. Rapid-fire analyses cover the relationship between alcohol consumption and incident atrial fibrillation, pulse self-examination as a simple strategy to improve AF detection, and emerging mechanistic research on caveolae, pacemaker signaling, sinus node dysfunction, and heart failure. The episode translates randomized trials, meta-analysis, screening research, and translational science into practical implications for the EP lab, clinic, patient counseling, and shared decision-making. Essential listening for electrophysiologists, cardiologists, fellows, advanced practice clinicians, and cardiac rhythm-management teams

    EP Edge × HRS Podcast: CT-Guided VT Ablation & LAA Closure Without AF: InEurHeart and OPINION, Caveolae, Alcohol and AFib, Pulse check and Afib Diagnosis

  5. Jul 6

    EP Edge® Journal Watch Issue 28, July 2026: Pulsed Field Ablation Goes Mainstream, LAAO vs DOACs, Non-PV Triggers, and LBBAP Lead Position

    In EP Edge® Journal Watch Issue 28, July 2026, Dr. Sharma reviews a major month in cardiac electrophysiology, where new technology is being tested against real-world evidence. This episode covers the rapid commercial adoption of pulsed field ablation, the NCDR AFib Ablation Registry, the VOLT-AF IDE balloon-in-basket PFA study, PFA-related intravascular hemolysis, and the evolving role of non-pulmonary vein triggers in first-time AF ablation. The issue also explores low-cost atrial fibrillation screening with pulse self-exam, next-generation left atrial appendage occlusion with the VERITAS Amulet 360 study, MAUDE registry safety signals for pericardial effusion after Watchman and Amulet, WATCHMAN peridevice leak anatomy by TEE and CT, the randomized evidence comparing LAAC vs DOACs, and whether left bundle branch area pacing lead position matters after conduction system capture. The central question across the issue: how should electrophysiologists match technology to mechanism, anatomy, substrate, and patient phenotype? The newsletter groups the papers into PFA scale and safety, AF beyond the pulmonary veins, LAAO in the evidence era, and conduction system pacing.  For full references, graphics, and the written newsletter, visit EP Edge Journal Watch on LinkedIn and Substack. EP Edge® Journal Watch Issue 28 reviews pulsed field ablation, LAAO vs DOACs, non-PV triggers, AF screening, WATCHMAN leaks, Amulet 360, and LBBAP. EP Edge Journal Watch, EP Edge podcast, cardiac electrophysiology, electrophysiology podcast, atrial fibrillation, AF ablation, pulsed field ablation, PFA, left atrial appendage occlusion, LAAO, conduction system pacing Trials NCDR AFib Ablation Registry, PFA commercial release, VOLT-AF IDE, balloon-in-basket PFA, PFA hemolysis, intravascular hemolysis, non-PV triggers, first-time AF ablation, pulse self-exam, AF screening, VERITAS study, Amulet 360, MAUDE registry, Watchman pericardial effusion, Amulet pericardial effusion, WATCHMAN peridevice leak, LAAC vs DOACs, LBBAP lead position, left bundle branch area pacing, myocardial work, Burri Jastrzębski, Tapia Martínez Clinical topic keywords: pulmonary vein isolation, PVI, persistent atrial fibrillation, paroxysmal atrial fibrillation, AF recurrence, AF stroke prevention, device-related thrombus, peridevice leak, TEE, cardiac CT, ischemic stroke, bleeding risk, DOAC therapy, physiologic pacing, left bundle branch pacing, electrophysiology research, Heart Rhythm Society Show Notes Links Substack https://lnkd.in/e6b2ZrbZ EP Edge Journal Watch Weekly Newsletter https://lnkd.in/e-Wa4diC EP Edge Newsletter In-Depth Monthly Issues https://lnkd.in/ep3NdZUz EP Edge Podcast Apple: https://lnkd.in/e5KfepBZ Spotify: https://lnkd.in/egb6HzPc Amazon: https://lnkd.in/e2q-xJi6 YouTube: https://lnkd.in/ePSUJCP2

    EP Edge® Journal Watch Issue 28, July 2026: Pulsed Field Ablation Goes Mainstream, LAAO vs DOACs, Non-PV Triggers, and LBBAP Lead Position

  6. Jun 29

    EP Edge® Journal Watch, Issue 27, June 2026: CT-Guided VT Ablation, PFA Safety, Posterior Wall Isolation, and AF Substrate Precision

    In this episode of EP Edge® Journal Watch, Dr. Sharma reviews the June 2026 Issue 27 newsletter, focusing on a central question in modern cardiac electrophysiology: how do we better match mechanism to intervention? This issue explores smarter procedural targeting, safer energy delivery, functional substrate assessment, and the evolving biology of atrial and ventricular arrhythmias. The episode begins with the InEurHeart trial, a randomized study of CT-guided ventricular tachycardia ablation in ischemic cardiomyopathy. Dr. Sharma explains why preprocedural cardiac CT may help identify scar-related VT isthmuses, shorten procedure time, and create a more reproducible workflow, while also discussing why anatomy alone cannot fully replace functional electroanatomic mapping. The discussion then moves to posterior wall isolation in persistent atrial fibrillation, including a study of very high-output pace-capture testing. The key clinical question is whether more aggressive confirmation of posterior wall inexcitability improves outcomes. The results challenge the assumption that more lesions, more energy, and stricter capture endpoints necessarily produce better rhythm control. Next, the episode examines CTI DEEP mapping, or decrement evoked potentials, as a functional electrophysiology marker for atrial flutter susceptibility in patients undergoing AF ablation. Dr. Sharma explains what DEEP is, how it is measured using extrastimulus pacing from the lateral tricuspid annulus and proximal coronary sinus, and why functional conduction delay may be more informative than CTI anatomy alone. The procedural safety conversation continues with a mechanistic study of left bundle branch area pacing showing that sheath withdrawal may be a vulnerable phase for septal perforation. This section highlights why a pacing lead that appears stable after deployment may still be mechanically vulnerable during early sheath withdrawal, especially in constrained right atrial anatomy. The episode then turns to pulsed field ablation safety, reviewing the HEMO-PFA study and a renal biomarker study after PFA. These papers explore hemolysis, myocardial injury, acute kidney injury, application burden, delayed creatinine changes, and why PFA safety should be considered patient-specific, lesion-set-specific, and system-specific rather than generic. In the atrial fibrillation substrate section, Dr. Sharma reviews the VISION Cardiac Surgery cohort on postoperative atrial fibrillation and its association with recurrent clinical AF, mortality, and heterogeneous stroke risk. The episode also reviews a state-of-the-art paper on inflammatory pathways in AF, including cytokines, NLRP3 inflammasome activation, oxidative stress, autonomic imbalance, epicardial adipose tissue, fibrosis, ion-channel remodeling, and why risk-factor modification should be viewed as substrate therapy. The final section covers modifiable exposure risk, including an experimental study of vaping coolants and ventricular arrhythmogenicity, followed by a nuanced discussion of alcohol intake and incident atrial fibrillation. Dr. Sharma emphasizes that the alcohol meta-analysis does not prove alcohol prevents AF; rather, it shows a nonlinear observational association, with very high intake clearly associated with increased AF risk. This episode is designed for electrophysiologists, cardiologists, EP fellows, advanced practice providers, cardiovascular researchers, and clinicians interested in atrial fibrillation, ventricular tachycardia, catheter ablation, pulsed field ablation, physiologic pacing, arrhythmia mechanisms, and evidence-based EP practice. For full references, figures, graphics, and detailed statistical interpretation, visit the EP Edge Journal Watch newsletter on LinkedIn and Substack at epedge.substack.com. Questions, suggestions, or concerns can be sent to epedge.cast@gmail.com.

    EP Edge® Journal Watch, Issue 27, June 2026: CT-Guided VT Ablation, PFA Safety, Posterior Wall Isolation, and AF Substrate Precision

  7. Jun 22

    EP Edge Journal Watch Issue 26, June 2026: PFA, LAAO, AF Ablation in Heart Failure, Myocarditis Risk and Sinus Node Biology

    In this episode of EP Edge Journal Watch Issue 26, June 2026, Dr. Sharma reviews high-impact studies shaping contemporary cardiac electrophysiology, with a focus on smarter ablation strategies, safer left atrial appendage closure, post-arrest and post-myocarditis risk stratification, and the cellular biology beneath cardiac rhythm. This episode covers pulsed field ablation beyond pulmonary vein isolation, including PVI plus posterior wall isolation in the PERSEPOLIS trial, and nanosecond pulsed field ablation as a potential strategy to reduce neuromuscular stimulation and improve procedural tolerance. Dr. Sharma also reviews catheter ablation for atrial fibrillation with left ventricular systolic dysfunction, focusing on CAMERA-MRI II and what cardiac MRI fibrosis means for recovery, patient selection, and counseling. The episode then moves into left atrial appendage occlusion, including outcomes in patients with reduced ejection fraction and simplified fluoroscopy-guided LAAO workflows. Additional discussions include epinephrine challenge after unexplained cardiac arrest and familial sudden death, the long-term risk of major arrhythmic events after myocarditis, and mechanistic studies on caveolae, pacemaker nanodomains, sinus node dysfunction, and the His-LBB twig as a source of premature ventricular complexes that can look almost identical to sinus rhythm. Rather than simply summarizing abstracts, this episode explains why each study was done, what clinical gap it was designed to address, how the methodology shaped the results, what the statistics mean in practical terms, and how the findings may influence real-world EP decision-making in the lab, clinic, and patient counseling. For full references, graphics, and the written analysis, read EP Edge Journal Watch on LinkedIn and Substack at epedge.substack.com. Keywords Cardiac electrophysiology, EP Edge, EP Edge Journal Watch, Dr. Sharma, electrophysiology podcast, cardiology podcast, heart rhythm, cardiac arrhythmias, atrial fibrillation, AFib, AF ablation, catheter ablation, pulsed field ablation, PFA, nanosecond PFA, pulmonary vein isolation, PVI, posterior wall isolation, PWI, persistent atrial fibrillation, paroxysmal atrial fibrillation, neuromuscular stimulation, AF ablation sedation, left atrial appendage occlusion, LAAO, left atrial appendage closure, reduced ejection fraction, heart failure, HFrEF, LV systolic dysfunction, cardiac MRI, late gadolinium enhancement, LV fibrosis, CAMERA-MRI II, PERSEPOLIS trial, ROSE-FLX, unexplained cardiac arrest, familial sudden death, epinephrine challenge, long QT syndrome, LQTS, CPVT, myocarditis, arrhythmic risk after myocarditis, ventricular arrhythmias, sudden cardiac death, sinus node dysfunction, caveolae, pacemaker nanodomains, His-Purkinje system, PVC ablation, His-LBB twig, premature ventricular complexes, MedEd, CME, cardiology education

    EP Edge Journal Watch Issue 26, June 2026: PFA, LAAO, AF Ablation in Heart Failure, Myocarditis Risk and Sinus Node Biology

  8. Jun 15

    EP Edge Journal Watch Issue 25 June 2026: AF Ablation, Left Atrial Appendage Closure, PFA Workflow, ICD Battery Longevity & Device Tradeoffs

    In EP Edge Journal Watch Issue 25, June 2026, Dr. Sharma reviews the most clinically relevant new studies in cardiac electrophysiology, with a focus on atrial fibrillation, stroke prevention, pulsed field ablation, ICD therapy, CRT strategy, and EP lab decision-making. This episode is built around the theme “Beyond the Binary” — moving past simple endpoints like recurrence versus no recurrence, PFA versus RF, EF below 35%, or lead versus no lead. The data in this issue challenge how electrophysiologists think about ablation success, anticoagulation strategy, left atrial appendage closure, device selection, ICD longevity, and arrhythmia risk. Topics covered include: LAAC after AF ablation and the OPTION bleeding-risk substudy: whether left atrial appendage closure after catheter ablation should be considered beyond traditionally high HAS-BLED patients, and how LAAC compares with long-term oral anticoagulation for bleeding reduction and stroke prevention. Female sex and AF stroke risk: a large TriNetX analysis asking whether female sex is truly a uniform stroke-risk factor in atrial fibrillation or better understood as an age- and comorbidity-dependent risk modifier. PFA versus radiofrequency ablation for early recurrence: why pulsed field ablation may reduce symptomatic early recurrence after pulmonary vein isolation, but why early recurrence after PFA still strongly predicts later atrial arrhythmia recurrence. AF burden after ablation: a 4-year continuous-monitoring study showing why binary recurrence endpoints may underestimate meaningful clinical benefit, and why AF burden reduction may be a more patient-centered ablation outcome. Timing of recurrence after paroxysmal AF ablation — pooled trial data suggesting that most post-ablation recurrences are front-loaded, raising important questions about optimal follow-up duration in AF ablation trials. Left atrial size in persistent AF ablation: CAPLA substudy data showing that left atrial volume index may not predict binary recurrence, but may predict recurrence burden and persistent recurrence phenotype. PFA thrombo-inflammation and hemolysis: a detailed look at systemic biological effects after pentaspline PFA, including hemolysis, nitric oxide reduction, renal safety, inflammation, platelet activation, and practical implications for pulse discipline. Optimized pentaspline PFA workflow: systematic remapping data showing that procedural workflow refinement can dramatically improve PVI durability, suggesting that pulmonary vein reconnection may often be a workflow problem rather than a waveform problem. S-ICD therapy in prior monomorphic VT: registry data exploring whether prior monomorphic ventricular tachycardia should automatically exclude patients from subcutaneous ICD therapy, especially when ablation is part of the strategy. CRT-DX versus conventional CRT-D: a randomized noninferiority trial asking whether selected CRT candidates without sinus node dysfunction truly need a dedicated atrial lead. ICD battery longevity by manufacturer, lead burden, and programming: a major device-management study showing clinically meaningful differences in battery longevity across ICD types and manufacturers, including how lead count, programmed output, and pulse width may affect generator replacement risk and lifetime cost. Competing risk in primary prevention ICD therapy: pooled MADIT and RAID data showing that very low LVEF is associated with both higher VT/VF risk and higher competing mortality, refining how clinicians should discuss ICD benefit in advanced heart failure. The nearly zero VA-interval trap: an EP lab pearl on slow-slow AVNRT with prolonged lower common pathway conduction, and why a near-zero VA interval can mimic typical AVNRT. Listen for a practical, clinically focused discussion of how these studies may influence AF ablation follow-up, LAAC selection, PFA workflow, ICD and CRT device choice, sudden death prevention, and EP lab diagnosis. EP Edge Journal Watch is also available as a LinkedIn newsletter and on Substack at epedge.substack.com. References, graphics, and links to the full newsletter are available there. Questions, suggestions, or concerns: epedge.cast@gmail.com Keywords: cardiac electrophysiology, EP Edge Journal Watch, atrial fibrillation, AF ablation, pulsed field ablation, PFA, radiofrequency ablation, pulmonary vein isolation, PVI, left atrial appendage closure, LAAC, OPTION trial, WATCHMAN FLX, AF burden, ICD battery longevity, implantable cardioverter defibrillator, S-ICD, CRT-DX, cardiac resynchronization therapy, ventricular tachycardia, sudden cardiac death, AVNRT, Heart Rhythm, electrophysiology podcast, cardiology podcast.

    EP Edge Journal Watch Issue 25 June 2026: AF Ablation, Left Atrial Appendage Closure, PFA Workflow, ICD Battery Longevity & Device Tradeoffs
See All (39)

5
out of 5
10 Ratings

About

Welcome to EP Edge Journal Watch — where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this bi-weekly podcast distills high-impact cardiovascular and EP research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal — not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve

Information

  • Creator
    Niraj Sharma MD FACC FHRS
  • Years Active
    2025 - 2026
  • Episodes
    39
  • Rating
    Clean
  • Copyright
    © 2026 Niraj Sharma MD FACC FHRS

You Might Also Like